Wong Kin Sang – Country Manager, Lundbeck Malaysia
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Address: Peti #8, Wisma Selangor Dredging, 5th Floor, South Block, 142-A, Jalan Ampang, 50450 Kuala Lumpur, Malaysia
Tel: +603 2161 4181
Web: http://www.ranbaxy.com/operations/operationcountry.aspx?Cid=67&flag=&Rid=61
Ranbaxy Laboratories Limited (Ranbaxy), India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.
Ranbaxy’s mission is ‘To become a Research-based International Pharmaceutical Company’. The Company is driven by its vision to ‘Achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets’.
Recognized as a leading manufacturer, Ranbaxy Malaysia was set up as a wholly owned subsidiary in June 1984.
With its excellent sales and marketing team, who are experienced and well versed with the industry, the company today has strong brand recognition amongst the General Practitioners, Government Hospitals and Retail Pharmacy sector. The marketing and distribution of Ranbaxy’s products is also undertaken for Schwarz Pharma and Desitin, Germany and Pharmascience, Canada.
Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales.
Ranbaxy’s diverse product basket of over 5,000 SKUs available in over 125 countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare trends project that the chronic treatment segments will outpace the acute treatment segments, primarily driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments.
Top 10 Products (2009)
• Valacyclovir
• Simvastatin
• Co-Amoxyclav
• Ciprofloxacin and Combinations
• Amoxycillin and Combinations
• Isotretinoin
• Ketorolac Tromethamine
• Loratadine and Combinations
• Ginseng+Vitamins
• Cephalexin
• Atorvastatin and Combinations
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Dr Hyzan Mohd Yusof, CEO at OSA Technology, tells the story of how he founded the company to address Malaysia’s unmet needs in medical devices as well as his vision…
How Malaysia is setting itself up to provide biosimilars across the Islamic world as well as Asia. Inno Bio Ventures, a Malaysian state-owned company originally set up to create…
Dr Ramli Zainal, the director at National Pharmaceutical Regulatory Agency (NPRA), expresses the continuous work of NPRA to build a strong regulatory ecosystem in Malaysia and the important role that…
Tan Sri Rahman Mamat, chairman of Inno Bio Ventures, provides his vision for biosimilars’ potential in Malaysia, and the progress the company has made in laying the foundations to make…
George Kazzi, general manager of Baxter Malaysia, highlights the main areas of development for his affiliate, including the introduction of more renal dialysis innovation as well as increasing awareness and…
Dr Dhesi Baha Raja, consultant in digital technologies at the Malaysian Ministry of Health, introduces the government’s plan to enter digital health through electronic medical records (EMR) and shares his…
Kshitij Panse, director of Servier Malaysia discusses the company’s planned move into oncology, as well as their strategies to provide an all-round improved patient experience, through education, screening, and e-health.…
Datuk Dr Noor Hisham Abdullah, director general of health at the Ministry of Health of Malaysia unveils the government’s plan to bring healthcare back to the community, and create a…
Dr. Azrul Mohd Khalib, chief executive at the Galen Centre for Health and Social Policy, gives an insight on the current important issues the Malaysian healthcare ecosystem is facing and…
Malaysia’s multi-ethnic population, disease burden, medical infrastructure and research speed, combined with its population’s proficiency in English, make the Southeast Asian nation a potentially excellent regional clinical trials destination. …
Shahnas Oli Mohamed, the managing director of Natural Wellness Holdings Sdn Bhd, expresses the important work that Natural Wellness has done to provide natural healthcare products to Malaysian patients, including…
See our Cookie Privacy Policy Here